177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer

• Published in: Biomedicines Vol. 9; no. 4; p. 430
• Main Authors: Sanli, Yasemin, Simsek, Duygu Has, Sanli, Oner, Subramaniam, Rathan M., Kendi, Ayse Tuba
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 15.04.2021; MDPI
• Subjects: 177Lu-PSMA; Androgens; Antigens; Bone marrow; Cancer therapies; Castration; Clinical trials; CRPC; Dosimetry; Drug dosages; Hydration; Ligands; Metastases; Metastasis; Patients; Prostate cancer; PSA; Radiation therapy; Review; Toxicity; United States > US
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines9040430

The aim of this narrative review is to evaluate the current status of 177Lu-PSMA (prostate specific membrane antigen) therapy for metastatic castration-resistant prostate cancer (mCRPC) in the light of the current literature. We also addressed patient preparation, therapy administration and side effect profiles. 177Lu-PSMA therapy efficacy was assessed by using prospective trials, meta-analyses and major retrospective trials. Predictors of efficacy were also mentioned. Although there are some different approaches regarding the use of 177Lu-PSMA therapy in different countries, this type of therapy is generally safe, with a low toxicity profile. From the oncological point of view, a PSA (prostate specific antigen) decline of ≥50% was seen in 10.6–69% of patients with mCRPC; whereas progression-free survival (PFS) was reported to be 3–13.7 months in different studies. Consequently, 177Lu-PSMA therapy is a promising treatment in patients with mCRPC, with good clinical efficacy, even in heavily pretreated patients with multiple lines of systemic therapy. Currently, there are ongoing clinical trials in the United States, including a phase III multicenter FDA registration trial.